China-based Contract Development and Manufacturing Organization (CDMO) Pharmaron Beijing Co., Ltd (HKG: 3759, SHE: 300759) has announced the receipt of a substantial grant from the UK government’s Life Sciences Innovation Manufacturing Fund (LSMIF). The grant will facilitate the expansion of Pharmaron’s existing viral vector and DNA manufacturing facility in Liverpool, with the company committing to invest GBP 151 million (USD 187 million) into the site, adding 3,500 square meters of commercial-scale GMP manufacturing capacity.
Liverpool Facility Acquisition and Current Operations
Pharmaron acquired the Liverpool cell and gene therapy (CGT) site from AbbVie (NYSE: ABBV) in 2021, which was previously Allergan’s global center of excellence for biologic drug substance development. The facility is a hub for gene therapy process development, including the production of viral vectors, DNA, and RNA drug substances, as well as drug product formulation services. Currently, the site is managing 29 separate projects, highlighting its importance in the field of gene therapy.
Strategic Investment and Growth Prospects
The investment in the Liverpool facility is a strategic move for Pharmaron, aligning with the growing global demand for advanced therapies and the production capabilities necessary to support them. The expansion will not only enhance Pharmaron’s manufacturing capabilities but also contribute to the UK’s life sciences sector, reinforcing the country’s position as a leader in innovative manufacturing.-Fineline Info & Tech
